1. Home
  2. CPB vs CNTA Comparison

CPB vs CNTA Comparison

Compare CPB & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Campbell Soup Company

CPB

Campbell Soup Company

HOLD

Current Price

$22.88

Market Cap

6.5B

ML Signal

HOLD

Logo Centessa Pharmaceuticals plc

CNTA

Centessa Pharmaceuticals plc

HOLD

Current Price

$39.69

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPB
CNTA
Founded
1869
2020
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
6.1B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
CPB
CNTA
Price
$22.88
$39.69
Analyst Decision
Hold
Buy
Analyst Count
18
9
Target Price
$26.06
$43.17
AVG Volume (30 Days)
8.2M
1.2M
Earning Date
06-01-2026
05-13-2026
Dividend Yield
7.63%
N/A
EPS Growth
6.35
29.13
EPS
1.55
N/A
Revenue
$10,253,000,000.00
$15,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.11
N/A
P/E Ratio
$14.28
N/A
Revenue Growth
6.40
N/A
52 Week Low
$19.56
$11.77
52 Week High
$34.18
$40.26

Technical Indicators

Market Signals
Indicator
CPB
CNTA
Relative Strength Index (RSI) 74.22 63.87
Support Level $19.78 $39.36
Resistance Level $31.86 $39.90
Average True Range (ATR) 0.77 0.15
MACD 0.26 -0.13
Stochastic Oscillator 95.79 45.57

Price Performance

Historical Comparison
CPB
CNTA

About CPB Campbell Soup Company

Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.

About CNTA Centessa Pharmaceuticals plc

Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.

Share on Social Networks: